Dr Reddy's Q2 Net Profit Falls 36% Amid Lower North America Sales, Plans Semaglutide Relaunch
Dr Reddy's Laboratories reported a 36% year-on-year decline in Q2 net profit to around Rs 913-925 crore, with revenue falling about 1.5% to approximately Rs 8,670 crore. The profit drop was mainly due to lower sales of the cancer drug lenalidomide in North America and a decline in active pharmaceutical ingredient volumes. However, the company saw double-digit growth in India and emerging markets, and sequential profit more than doubled from Q1 as semaglutide-related provisions eased. The firm plans to relaunch semaglutide in multiple markets, including Canada, in November.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 42/100.
Outlets measured: businessstandard, news18, economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 23 Oct, 12:34 pm. Other outlets followed.